CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, a neuromodulation device that enhance symptoms for patients with heart failure by delivering electrical pulses to baroreceptors. It sells its products through direct sales force, sales agents, and independent distributors. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [11/06/2026 10:29 PST] CVRx, Inc (NASDAQ:CVRX), Down By 100% ($1.4) From $1.4 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [10/29/2026 07:15 PDT] CVRX Expected to Trade Down After Bearish Patterns Develop
• [10/13/2026 16:11 PDT] CVRx, Inc (NASDAQ:CVRX), Down By 100% ($1.53) From $1.53 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [10/02/2026 06:49 PDT] CVRX Expected to Trade Down After Bearish Patterns Develop
• [09/30/2026 21:22 PDT] Market Maker Surveillance Report. CVRX, Losing Stocks With Lowest Price Friction For Wednesday, September 30th 2026
• [09/17/2026 05:45 PDT] CVRX Expected to Trade Up After Bullish Patterns Develop